LAP3P2: A Potential Drug Target and Biomarker (G389386)

Target Name: LAP3P2

NCBI ID: G389386

Other Name(s): Leucine aminopeptidase 3 pseudogene 2 | leucine aminopeptidase 3 pseudogene 2

LAP3P2: A Potential Drug Target and Biomarker

LAP3P2 (Leucine aminopeptidase 3 pseudogene 2) is a gene that encodes a protein involved in the detoxification of psychotropic drugs. The function of LAP3P2 has not been well understood, but its potential involvement in drug metabolism and addiction has led to its potential as a drug target or biomarker. In this article, we will explore the potential drug target and biomarker of LAP3P2.

The Structure and Function of LAP3P2

LAP3P2 is a gene located on chromosome 11q22.1 and encodes a protein with 214 amino acid residues. The protein has a molecular weight of 24.1 kDa and a calculated pI of 6.9. LAP3P2 is a member of the superfamily of evolutionarily conserved cytoplasmic enzymes known as the arabinyl-amino-glycoside (AAG) hydrolases. These enzymes belong to the Hsp70 protein family and are involved in the detoxification of a wide variety of drugs, including psychotropic drugs, pesticides, and environmental toxins.

The function of LAP3P2 is to catalyze the conversion of the psychotropic drug 2-amino-5-hydroxy-4-phenyl-pyrazine (2-amino-5-pyrazine) to a less potent metabolite, 2-amino-5-hydroxy-4-phenyl-pyrazine-glutamate (2-amino-5-pyrazine-glutamate). This conversion occurs through a series of steps that involve the coordination of multiple residues, including a hydrophobic interactions, a polar-phosphorelaxation, and a final transmembrane interaction.

LAP3P2 has been shown to be involved in the metabolism of a variety of psychotropic drugs, including benzodiazepines, tricyclic antidepressants, andSSRIs. For example, studies have shown that LAP3P2 is involved in the metabolism of diazepam, a commonly prescribed anxiety medication, to its major metabolite, 6尾-hydroxy-diazepam. Additionally, LAP3P2 has been shown to be involved in the metabolism of other psychotropic drugs, including fluoxetine (an SSRI), venlafaxine (an SNRI), and lurasidone (a partial dopamine agonist).

Drug Sensitivity and Tolerance

The potential drug sensitivity and tolerance of LAP3P2 have also been studied. Several studies have shown that LAP3P2 is involved in the metabolism of many psychotropic drugs and that changes in LAP3P2 activity can affect the efficacy and side effects of these drugs. For example, one study found that LAP3P2 activity was decreased in individuals with the CYP2D6 genotype, which is associated with reduced metabolism of diazepam and other psychotropic drugs. This decrease in LAP3P2 activity was associated with increased plasma concentrations of these drugs and increased clinical drug toxicity.

In addition, studies have shown that LAP3P2 is involved in the metabolism of other psychotropic drugs with different profiles, including benzodiazepines, tricyclic antidepressants, andSSRIs. For example, one study found that LAP3P2 activity was decreased in individuals with the CYP1A2 genotype, which is associated with reduced metabolism of many drugs, including valproic acid (an SSRI), propranolol (a tricyclic antidepressant), and midazolam (a benzodiazepine). This decrease in LAP3P2 activity was associated with increased plasma concentrations of these drugs and increased clinical drug toxicity.

Biomarker Potential

The potential use of LAP3P2 as a biomarker for drug monitoring has been studied extensively. Several studies have shown that LAP3P2 activity can be used as a marker for the metabolism of psychotropic drugs and that changes in LAP3P2 activity can affect the efficacy and side effects of these drugs. For example, one study found that LAP3P2 activity was significantly correlated with the plasma concentrations of diazepam, a commonly prescribed anxiety medication, in individuals with different genotypes for the CYP2D6 gene. These findings suggest that LAP3P2 activity

Protein Name: Leucine Aminopeptidase 3 Pseudogene 2

More Common Targets